Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Explore the development and clinical applications of Memorial Sloan Kettering's comprehensive genomic profiling programs through this 59-minute webinar presented by Dr. Michael Berger, Co-Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at MSK. Learn about MSK-IMPACT, an FDA-authorized tumor sequencing panel that has profiled over 100,000 tumors, and MSK-ACCESS, a clinically validated plasma cell-free DNA assay used to study tumor evolution and drug resistance. Discover how matched tumor-normal sequencing reduces biological false positives while enabling accurate somatic variant identification and seamless germline analysis integration. Examine the critical role of SOPHiA GENETICS as a collaborator in expanding precision oncology accessibility through scalable, cloud-based solutions. Analyze real clinical cases demonstrating how these genomic technologies inform treatment decision-making, identify clonal hematopoiesis of indeterminate potential (CHIP), and detect resistance mechanisms. Gain insights into how this matched tumor-normal approach enhances diagnosis and treatment planning while improving precision in oncology treatment strategies across diverse tumor types.
